Kezar Life Sciences, Inc. (NASDAQ:KZR) Major Shareholder Morningside Venture Investment Sells 28,700 Shares

0

Kezar Life Sciences, Inc. (NASDAQ: KZR – Get an assessment) top shareholder Morningside Venture Investment sold 28,700 shares of the company in a transaction that took place on Monday, October 3. The stock was sold at an average price of $8.78, for a total value of $251,986.00. Following the completion of the sale, the insider now owns 6,080,352 shares of the company, valued at approximately $53,385,490.56. The transaction was disclosed in an SEC filing, available at this link. Major shareholders who own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Kezar Life Sciences Stock Performance

Shares of KZR traded down $0.23 during trading hours on Wednesday, hitting $8.28. 771,155 shares of the company were traded, against an average volume of 1,313,077. The company has a current ratio of 39.64, a quick ratio of 39.64 and a debt ratio of 0.03. The company has a 50-day moving average of $9.58 and a 200-day moving average of $9.74. Kezar Life Sciences, Inc. has a fifty-two-week low of $4.30 and a fifty-two-week high of $18.55.

Kezar Life Sciences (NASDAQ:KZR – Get an assessment) last reported quarterly earnings data on Thursday, August 11. The company reported ($0.25) earnings per share for the quarter, beating analyst consensus estimates of ($0.27) by $0.02. On average, equity research analysts expect Kezar Life Sciences, Inc. to post -1.07 EPS for the current fiscal year.

Wall Street analysts predict growth

Several equity research analysts have commented on the company. Jonestrading raised its price target on Kezar Life Sciences from $17.00 to $20.00 in a research report on Tuesday, June 28. Wells Fargo & Company raised its price target on Kezar Life Sciences from $13.00 to $17.00 and gave the stock an “overweight” rating in a Tuesday, June 28 research report. Finally, HC Wainwright raised its price target on Kezar Life Sciences from $20.00 to $21.00 and gave the stock a “buy” rating in a Friday, August 12 research report.

Hedge funds weigh on Kezar Life Sciences

Hedge funds and other institutional investors have recently changed their stakes in the company. Dorsey Wright & Associates acquired a new position in Kezar Life Sciences during the first quarter worth $60,000. Amalgamated Bank acquired a new position in Kezar Life Sciences stock during Q1 worth approximately $70,000. Qube Research & Technologies Ltd bought a new stake in shares of Kezar Life Sciences in the first quarter worth approximately $167,000. Fox Run Management LLC acquired a new stake in Kezar Life Sciences during the first quarter worth approximately $180,000. Finally, Arizona State Retirement System bought a new position in Kezar Life Sciences during the second quarter worth about $95,000. 91.01% of the shares are held by hedge funds and other institutional investors.

About Kezar Life Sciences

(Get an assessment)

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapies to address unmet needs in immune-mediated diseases and cancer in the United States . The Company’s lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis and polymyositis; and phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis.

Further reading

This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Kezar Life Sciences, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Kezar Life Sciences didn’t make the list.

While Kezar Life Sciences currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

Share.

About Author

Comments are closed.